Cargando…
Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seropr...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500479/ https://www.ncbi.nlm.nih.gov/pubmed/36159252 http://dx.doi.org/10.3389/fpubh.2022.989337 |
_version_ | 1784795231571410944 |
---|---|
author | Willeit, Peter Kimpel, Janine Winner, Hannes Harthaller, Teresa Schäfer, Helena Bante, David Falkensammer, Barbara Rössler, Annika Riepler, Lydia Ower, Cornelia Sacher, Magdalena von Laer, Dorothee Borena, Wegene |
author_facet | Willeit, Peter Kimpel, Janine Winner, Hannes Harthaller, Teresa Schäfer, Helena Bante, David Falkensammer, Barbara Rössler, Annika Riepler, Lydia Ower, Cornelia Sacher, Magdalena von Laer, Dorothee Borena, Wegene |
author_sort | Willeit, Peter |
collection | PubMed |
description | In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seroprevalence of SARS-CoV-2 among the adult population in the district of Schwaz at the time of the implementation. Data on previous history of infections, symptoms and immunization status were collected using a structured questionnaire. Blood samples were used to determine SARS-CoV-2 specific anti-spike, anti-nucleocapsid and neutralizing antibodies. We recruited 2,474 individuals with a median age (IQR) of 42 (31–54) years. Using the official data on distribution of age and sex, we found a standardized prevalence of undocumented infections at 15.0% (95% CI: 13.2–16.7). Taken together with the officially documented infections, we estimated that 24.0% (95% CI: 22.5–25.6) of the adult population had prior SARS-CoV-2 infection. Hence, the proportion of undocumented infections identified by our study was 55.8% (95% CI: 52.7–58.5). With a vaccination coverage of 10% among the adults population at that time, we imply that a minimum of two-thirds of the target popuation was susceptible to the circulating threat when this unique campaign started. |
format | Online Article Text |
id | pubmed-9500479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95004792022-09-24 Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak Willeit, Peter Kimpel, Janine Winner, Hannes Harthaller, Teresa Schäfer, Helena Bante, David Falkensammer, Barbara Rössler, Annika Riepler, Lydia Ower, Cornelia Sacher, Magdalena von Laer, Dorothee Borena, Wegene Front Public Health Public Health In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seroprevalence of SARS-CoV-2 among the adult population in the district of Schwaz at the time of the implementation. Data on previous history of infections, symptoms and immunization status were collected using a structured questionnaire. Blood samples were used to determine SARS-CoV-2 specific anti-spike, anti-nucleocapsid and neutralizing antibodies. We recruited 2,474 individuals with a median age (IQR) of 42 (31–54) years. Using the official data on distribution of age and sex, we found a standardized prevalence of undocumented infections at 15.0% (95% CI: 13.2–16.7). Taken together with the officially documented infections, we estimated that 24.0% (95% CI: 22.5–25.6) of the adult population had prior SARS-CoV-2 infection. Hence, the proportion of undocumented infections identified by our study was 55.8% (95% CI: 52.7–58.5). With a vaccination coverage of 10% among the adults population at that time, we imply that a minimum of two-thirds of the target popuation was susceptible to the circulating threat when this unique campaign started. Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9500479/ /pubmed/36159252 http://dx.doi.org/10.3389/fpubh.2022.989337 Text en Copyright © 2022 Willeit, Kimpel, Winner, Harthaller, Schäfer, Bante, Falkensammer, Rössler, Riepler, Ower, Sacher, von Laer and Borena. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Willeit, Peter Kimpel, Janine Winner, Hannes Harthaller, Teresa Schäfer, Helena Bante, David Falkensammer, Barbara Rössler, Annika Riepler, Lydia Ower, Cornelia Sacher, Magdalena von Laer, Dorothee Borena, Wegene Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak |
title | Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak |
title_full | Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak |
title_fullStr | Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak |
title_short | Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak |
title_sort | seroprevalence of sars-cov-2 infection in the tyrolean district of schwaz at the time of the rapid mass vaccination in march 2021 following b.1.351-variant outbreak |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500479/ https://www.ncbi.nlm.nih.gov/pubmed/36159252 http://dx.doi.org/10.3389/fpubh.2022.989337 |
work_keys_str_mv | AT willeitpeter seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT kimpeljanine seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT winnerhannes seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT harthallerteresa seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT schaferhelena seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT bantedavid seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT falkensammerbarbara seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT rosslerannika seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT rieplerlydia seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT owercornelia seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT sachermagdalena seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT vonlaerdorothee seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak AT borenawegene seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak |